Gyros AB, a leader in utilization of microfluidic technologies to miniaturize and automate immunoassays, announced today that GE Healthcare Life Sciences has become sole distributor for the company’s nanoliter-scale immunoassay platform in China, Taiwan and Hong Kong. The Gyros platform (gyros.com) is used by major biopharmaceutical companies and their service providers to improve productivity and efficiency during the development of biotherapeutics and vaccines, boosting time-critical workflows and helping to meet regulatory demands.
Commenting on the announcement, Erik Walldén, CEO at Gyros, said,“The acceptance of our nanoliter-scale immunoassay platform continues to grow within the global biopharmaceutical industry. Expansion into the Asian markets through an experienced and respected network of distributors will ensure the highest possible standards of service and support for customers interested in our products, which we see as one of the key factors for commercial success in this region. Having recently signed with GE Healthcare Japan, we are very pleased to extend our collaboration into China, Taiwan and Hong Kong through such a well-established supplier.”
Duncan Yu, General Manager, Life Sciences of GE Healthcare Greater China, added,“We are delighted to have signed this agreement with Gyros which will help us further expand our offering of value-added and innovative technologies to the rapidly growing biopharmaceutical industry in China, Taiwan and Hong Kong. The Gyros immunoassay platform offers manufacturers of biopharmaceuticals and vaccines the potential to make substantial improvements in productivity and is an excellent complement to our own extensive range of analytical technologies for the biopharmaceutical industry including Biacore™ and MicroCal™ systems.”
About Gyros AB
Gyros AB is the world leader in utilization of microfluidic technologies to miniaturize and automate immunoassays. The Gyros™ immunoassay platform increases productivity and efficiency during development of biotherapeutics and vaccines, saving time and labor. Major biopharmaceutical companies and their service providers utilize the Gyros platform to boost time-critical workflows and meet increasing regulatory demands.
Spanning the entire spectrum of immunoassays, the platform cuts the time to result significantly. Faster development times, and unattended running of assays at nanoliter scale, save labor and sample. The ease of assay transfer between sites and from development to regulated environments is unsurpassed in the industry.
The company has around 60 employees, based at its headquarters in Uppsala, Sweden and at regional sales and support offices in the USA and Europe, and a growing network of distributors.
About GE Healthcare
GE Healthcare (gehealthcare.com) provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems.
Our “healthymagination” vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality around the world. Headquartered in the United Kingdom, GE Healthcare is a unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employees are committed to serving healthcare professionals and their patients in more than 100 countries.
For more information about GE Healthcare Life Sciences’ technologies and services, please visit gelifesciences.com/.
For our latest news, please visit newsroom.gehealthcare.com/.